{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:44:43Z","timestamp":1790995483954,"version":"4.1.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune diseases are usually associated with environmental triggers and genetic predisposition. However, a few number of autoimmune diseases has a monogenic cause, mostly in children. These diseases may be the expression, isolated or associated with other symptoms, of an underlying inborn error of immunity (IEI). Autoimmune cytopenias (AICs), including immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), autoimmune neutropenia (AN), and Evans\u2019 syndrome (ES) are common presentations of immunological diseases in the pediatric age, with at least 65% of cases of ES genetically determined. Autoimmune cytopenias in IEI have often a more severe, chronic, and relapsing course. Treatment refractoriness also characterizes autoimmune cytopenia with a monogenic cause, such as IEI. The mechanisms underlying autoimmune cytopenias in IEI include cellular or humoral autoimmunity, immune dysregulation in cases of hemophagocytosis or lymphoproliferation with or without splenic sequestration, bone marrow failure, myelodysplasia, or secondary myelosuppression. Genetic characterization of autoimmune cytopenias is of fundamental importance as an early diagnosis improves the outcome and allows the setting up of a targeted therapy, such as CTLA-4 IgG fusion protein (Abatacept), small molecule inhibitors (JAK-inhibitors), or gene therapy. Currently, gene therapy represents one of the most attractive targeted therapeutic approaches to treat selected inborn errors of immunity. Even in the absence of specific targeted therapies, however, whole exome genetic testing (WES) for children with chronic multilineage cytopenias should be considered as an early diagnostic tool for disease diagnosis and genetic counseling.<\/jats:p>","DOI":"10.3389\/fimmu.2022.846660","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T05:02:10Z","timestamp":1649221330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets"],"prefix":"10.3389","volume":"13","author":[{"given":"Manuela","family":"Cortesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosa","family":"Soresina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cattalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Lougaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Badolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human Inborn Errors of Immunity: 2019 Update on the Classification From the International Union of Immunological Societies Expert Committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-020-00763-0","article-title":"Correction to: Human Inborn Errors of Immunity: 2019 Update on the Classification From the International Union of Immunological Societies Expert Committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.04.015","article-title":"Initial Presenting Manifestations in 16,486 Patients With Inborn Errors of Immunity Include Infections and Noninfectious Manifestations","volume":"148","author":"Thalhammer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000923","article-title":"Immune Dysregulation in Patients With RAG Deficiency and Other Forms of Combined Immune Deficiency","volume":"135","author":"Delmonte","year":"2020","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-11-887141","article-title":"Pediatric Evans Syndrome is Associated With a High Frequency of Potentially Damaging Variants in Immune Genes","volume":"134","author":"Hadjadj","year":"2019","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.420","article-title":"Immune Cytopenias as a Continuum in Inborn Errors of Immunity: An in-Depth Clinical and Immunological Exploration","volume":"9","author":"Zama","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583260","article-title":"Autoimmune and Other Cytopenias in Primary Immunodeficiencies: Pathomechanisms, Novel Differential Diagnoses, and Treatment","volume":"124","author":"Seidel","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00018-011-0838-8","article-title":"Genetic Disorders With Immune Dysregulation","volume":"69","author":"Gambineri","year":"2012","journal-title":"Cell Mol Life Sci CMLS"},{"key":"B10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jaip.2020.10.057","article-title":"Patterns of Immune Dysregulation in Primary Immunodeficiencies: A Systematic Review","volume":"9","author":"Mauracher","year":"2021","journal-title":"J Allergy Clin Immunol In Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000153","article-title":"Treatment of Immune-Mediated Cytopenias in Patients With Primary Immunodeficiencies and Immune Regulatory Disorders (PIRDs)","volume":"2020","author":"Seidel","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.hoc.2019.01.005","article-title":"Primary and Secondary Immune Cytopenias: Evaluation and Treatment Approach in Children","volume":"33","author":"Kim","year":"2019","journal-title":"Hematol\/Oncol Clinics North America"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.114561","article-title":"Treatment of Autoimmune Hemolytic Anemias","volume":"99","author":"Zanella","year":"2014","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2013.08.009","article-title":"Diagnosis and Management of Autoimmune Cytopenias in Childhood","volume":"60","author":"Teachey","year":"2013","journal-title":"Pediatr Clinics North Am"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04121-z","article-title":"Increased Proportion of Th17\/Treg Cells at the New Diagnosed Stage of Chronic Immune Thrombocytopenia in Pediatrics: The Pilot Study From a Multi-Center","volume":"180","author":"Gu","year":"2021","journal-title":"Eur J Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27260","article-title":"Diagnosis and Management of Chronic and Refractory Immune Cytopenias in Children, Adolescents, and Young Adults","volume":"65","author":"Rotz","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.14423\/SMJ.0000000000000637","article-title":"Autoimmune Neutropenia Updates: Etiology, Pathology, and Treatment","volume":"110","author":"Afzal","year":"2017","journal-title":"South Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1186\/s12879-021-06506-9","article-title":"Autoimmune Neutropenia Associated With Influenza Virus Infection in Childhood: A Case Report","volume":"21","author":"Callejas Caballero","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune Hemolytic Anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults: Recommendations From the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The Diagnosis and Management of Primary Autoimmune Haemolytic Anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br J Of Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm Autoimmune Hemolytic Anemia","volume":"381","author":"Brodsky","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16009","article-title":"Bortezomib and Dexamethasone, an Original Approach for Treating Multi-Refractory Warm Autoimmune Haemolytic Anaemia","volume":"187","author":"Fadlallah","year":"2019","journal-title":"Br J Of Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00590","article-title":"New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia","volume":"11","author":"Berentsen","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13319","article-title":"Autoimmune Thrombocytopenia: Current Treatment Options in Adults With a Focus on Novel Drugs","volume":"103","author":"Witkowski","year":"2019","journal-title":"Eur J Of Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13866","article-title":"How I Manage Evans Syndrome and AIHA Cases in Children","volume":"172","author":"Miano","year":"2016","journal-title":"Br J Of Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13336","article-title":"Long-Term Remission Rates After Splenectomy in Adults With Evans Syndrome Compared to Immune Thrombocytopenia: A Single-Center Retrospective Study","volume":"104","author":"Sulpizio","year":"2020","journal-title":"Eur J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00946","article-title":"The Changing Landscape of Autoimmune Hemolytic Anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of Mice and Men: An Open-Label Pilot Study for Treatment of Immune Thrombocytopenic Purpura by an Inhibitor of Syk","volume":"113","author":"Podolanczuk","year":"2009","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123859","article-title":"New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1","volume":"9","author":"Barcellini","year":"2020","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12739","article-title":"Pharmacokinetic-Pharmacodynamic Modelling of the Anti-FcRn Monoclonal Antibody Rozanolixizumab: Translation From Preclinical Stages to the Clinic","volume":"11","author":"Lledo-Garcia","year":"2022","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 Multiple-Dose Study of an FcRn Inhibitor, Rozanolixizumab, in Patients With Primary Immune Thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: A Review in Systemic Lupus Erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B34","article-title":"BAFF Level Increased in Patients With Autoimmune Hemolytic Anemia","volume":"8","author":"Zhao","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649182","article-title":"Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort","volume":"12","author":"Westermann-Clark","year":"2021","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13600","article-title":"Refractory Autoimmune Cytopenias in Pediatric Evans Syndrome With Underlying Systemic Immune Dysregulation","volume":"106","author":"Grimes","year":"2021","journal-title":"Eur J Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2015.11.004","article-title":"The Crossroads of Autoimmunity and Immunodeficiency: Lessons From Polygenic Traits and Monogenic Defects","volume":"137","author":"Grimbacher","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25769","article-title":"Combined Autoimmune Cytopenias Presenting in Childhood","volume":"63","author":"Al Ghaithi","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2021.04.005","article-title":"Immune Checkpoint Deficiencies and Autoimmune Lymphoproliferative Syndromes","volume":"44","author":"G\u00e1mez-D\u00edaz","year":"2021","journal-title":"Biomed J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744623","article-title":"Editorial: Thymic Epithelial Cells: New Insights Into the Essential Driving Force of T-Cell Differentiation","volume":"12","author":"Bosticardo","year":"2021","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2016.00086","article-title":"Novel Findings Into AIRE Genetics and Functioning: Clinical Implications","volume":"4","author":"De Martino","year":"2016","journal-title":"Front Pediatr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713301","article-title":"Autoimmune Polyendocrine Syndromes","volume":"378","author":"Husebye","year":"2018","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2004.09.009","article-title":"Aire: An Update","volume":"16","author":"Su","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200523087","article-title":"AIRE Deficiency in Thymus of 2 Patients With Omenn Syndrome","volume":"115","author":"Cavadini","year":"2005","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jaci.2009.06.048","article-title":"Reduced Central Tolerance in Omenn Syndrome Leads to Immature Self-Reactive Oligoclonal T Cells","volume":"124","author":"Somech","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.697230","article-title":"Genetic Basis of Altered Central Tolerance and Autoimmune Diseases: A Lesson From AIRE Mutations","volume":"31","author":"Capalbo","year":"2012","journal-title":"Int Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2015.07.007","article-title":"Autoimmune Disease in Primary Immunodeficiency: At the Crossroads of Anti-Infective Immunity and Self-Tolerance","volume":"35","author":"Saifi","year":"2015","journal-title":"Immunol Allergy Clinics North Am"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750542","article-title":"Regulatory T Cells: Regulation of Identity and Function","volume":"12","author":"Grover","year":"2021","journal-title":"Front Immunol"},{"key":"B49","article-title":"The Immunological Synapse as a Novel Therapeutic Target","volume":"7","author":"Teft","year":"2006","journal-title":"Curr Opin Investigational Drugs (London Engl 2000)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/nyas.12049","article-title":"Wiskott-Aldrich Syndrome: A Comprehensive Review","volume":"1285","author":"Massaad","year":"2013","journal-title":"Ann New York Acad Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.662645","article-title":"Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights Into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies","volume":"9","author":"G\u00e1mez-D\u00edaz","year":"2021","journal-title":"Front Pediatr"},{"key":"B52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1189\/jlb.5RI0516-237RR","article-title":"STAT Mutations as Program Switchers: Turning Primary Immunodeficiencies Into Autoimmune Diseases","volume":"101","author":"Lorenzini","year":"2017","journal-title":"J Leukocyte Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00847-x","article-title":"Human STAT1 Gain-Of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy","volume":"40","author":"Okada","year":"2020","journal-title":"J Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.026","article-title":"Tregopathies: Monogenic Diseases Resulting in Regulatory T-Cell Deficiency","volume":"142","author":"Cepika","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.03.017","article-title":"PI3K Pathway Defects Leading to Immunodeficiency and Immune Dysregulation","volume":"143","author":"Nunes-Santos","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-015-0187-8","article-title":"The Ying and Yang of STAT3 in Human Disease","volume":"35","author":"Vogel","year":"2015","journal-title":"J Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common Variable Immunodeficiency Disorders: Division Into Distinct Clinical Phenotypes","volume":"112","author":"Chapel","year":"2008","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204729","article-title":"Autoimmunity in Primary Immunodeficiency Disorders: An Updated Review on Pathogenic and Clinical Implications","volume":"10","author":"Costagliola","year":"2021","journal-title":"J Clin Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clim.2015.06.013","article-title":"Regulatory B Cells in CVID Patients Fail to Suppress Multifunctional IFN-\u03b3+ TNF-\u03b1+ CD4+ T Cells Differentiation","volume":"160","author":"Vlkova","year":"2015","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00210","article-title":"Pathogenesis of Autoimmunity in Common Variable Immunodeficiency","volume":"3","author":"Warnatz","year":"2012","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00636","article-title":"Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond","volume":"9","author":"de Valles-Ib\u00e1\u00f1ez","year":"2018","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08077.x","article-title":"Update on the Hyper Immunoglobulin M Syndromes","volume":"149","author":"Davies","year":"2010","journal-title":"Br J Haematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08738-9","article-title":"Clinical, Immunological, and Genetic Features in Patients With Activated Pi3k\u03b4 Syndrome (APDS): A Systematic Review","volume":"59","author":"Jamee","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1159\/000503997","article-title":"Targeted Therapy With Biologicals and Small Molecules in Primary Immunodeficiencies","volume":"29","author":"Delmonte","year":"2020","journal-title":"Med principles Pract Int J Kuwait Univ Health Sci Centre"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00337-7","article-title":"Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature","volume":"21","author":"Bevacqua","year":"2019","journal-title":"Paediatric Drugs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"108779","DOI":"10.1016\/j.clim.2021.108779","article-title":"Abatacept for Treatment-Refractory Pediatric CTLA4-Haploinsufficiency","volume":"229","author":"Lanz","year":"2021","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/blood.2021013496","article-title":"Abatacept is Useful in Auto-Immune Cytopenia With Immunopathologic Manifestations Caused by CTLA-4 Defects","volume":"139","author":"Dhunputh","year":"2021","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.jaip.2019.06.011","article-title":"Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency","volume":"7","author":"Kiykim","year":"2019","journal-title":"J Allergy Clin Immunol In Pract"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-Term Outcome of LRBA Deficiency in 76 Patients After Various Treatment Modalities as Evaluated by the Immune Deficiency and Dysregulation Activity (IDDA) Score","volume":"145","author":"Tesch","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the Treatment of Immune Dysregulation in Patients With Gain-of-Function Signal Transducer and Activator of Transcription 1 (STAT1) or STAT3 Mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and Immunologic Phenotype Associated With Activated Phosphoinositide 3-Kinase \u03b4 Syndrome 2: A Cohort Study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase \u03b4 Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase \u03b4 Syndrome Registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.032","article-title":"Hematopoietic Stem Cell Transplantation for Progressive Combined Immunodeficiency and Lymphoproliferation in Patients With Activated Phosphatidylinositol-3-OH Kinase \u03b4 Syndrome Type 1","volume":"143","author":"Okano","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic Stem Cell Transplant in Patients With Activated PI3K Delta Syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"Activated PI3K\u03b4 Syndrome\"-Targeted Therapy With the PI3K\u03b4 Inhibitor Leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.697706","article-title":"Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence","volume":"9","author":"Bloomfield","year":"2021","journal-title":"Front Pediatr"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648951","article-title":"Gene Therapies for Primary Immune Deficiencies","volume":"12","author":"Kohn","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.846660\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T05:02:13Z","timestamp":1649221333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.846660\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2022.846660"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.846660","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"article-number":"846660"}}